[HTML][HTML] Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year
LD Cornell, CA Schinstock, MJ Gandhi… - American Journal of …, 2015 - Elsevier
This study examined outcomes beyond 1 year in eculizumab-treated (EC) positive
crossmatch kidney transplants (+ XMKTx) compared to a historical control group.+ XMKTx
received desensitization with either plasma exchange (PE) alone (N= 48) or PE and EC (N=
30). EC, given for at least 1 month, was continued in the setting of persistently high DSA (B
flow cytometric crossmatch [BFXM]> 200) including: 4 weeks (n= 14); 9 weeks (n= 6), 6
months (n= 2), and 12 months (n= 8). All patients had at least 2 years follow-up. The …
crossmatch kidney transplants (+ XMKTx) compared to a historical control group.+ XMKTx
received desensitization with either plasma exchange (PE) alone (N= 48) or PE and EC (N=
30). EC, given for at least 1 month, was continued in the setting of persistently high DSA (B
flow cytometric crossmatch [BFXM]> 200) including: 4 weeks (n= 14); 9 weeks (n= 6), 6
months (n= 2), and 12 months (n= 8). All patients had at least 2 years follow-up. The …